Experimental Hematology
Volume 37, Issue 6 , Pages 649-658 , June 2009

Acute myelogenous leukemia

  • Joshua L. Shipley
    • ,
  • James N. Butera

      Affiliations

    • Corresponding Author InformationOffprint requests to: James N. Butera, M.D., Department of Hematology/Oncology, Brown University, Rhode Island Hospital, 593 Eddy Street, Providence, RI 02903

Received 2 June 2008 ,Revised 9 April 2009 ,Accepted 13 April 2009.

References 

  1. Farag SS, Ruppert AS, Mrozek K, et al. Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study. J Clin Oncol. 2005;23:482
  2. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Blood. 1998;92:2322-2233
  3. Farag SS, Archer KJ, Mrozek K, et al. Pretreatment cytogenetcs add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Blood. 2006;108:63–73
  4. Appelbaum FR, Kopecky KJ, Tallman MS, et al. The clinical spectrum of adult acute myeloid leukemia associated with core binding factor translocations. Br J Haematol. 2006;135:165–173
  5. Kuchenbauer F, Schnittger S, Look T, et al. Identification of additional cytogenetic and molecular genetic abnormalities in acute myeloid leukemia with t(8;21)/AML1-ETO. Br J Haematol. 2006;134:616–619
  6. Mrozek K, Bloomfield CD. Chromosome aberrations, gene mutations and expression changes, and prognosis in adult acute myeloid leukemia. Hematology Am Soc Hematol Educ Program. 2006;169–177
  7. Ichikawa H, Tanabe K, Mizushima H, et al. Common gene expression signatures in t(8;21)- and inv(16)-acute myeloid leukemia. Br J Haematol. 2006;135:336–347
  8. Paschka P, Marcucci G, Ruppert AS, et al. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. J Clin Oncol. 2006;24:3904–3911
  9. Mrozek K, Marcucci G, Paschka P, Whitman SP, Bloomfield CD. Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?. Blood. 2007;109:431–448
  10. Dillman RO, Davis RB, Green MR, et al. A comparative study of two different doses of cytarabine for acute myeloid leukemia: a phase III trial of Cancer and Leukemia Group B. Blood. 1991;78:2520–2526
  11. Weick JK, Kopecky KJ, Appelbaum FR, et al. A randomized investigation of high-dose versus standard –dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia; A Southwest Oncology Group Study. Blood. 1996;88:2841–2851
  12. Bishop JF, Matthews JP, Young GA, et al. A randomized study of high-dose cytarabine in induction acute myeloid leukemia. Blood. 1996;87:1710–1717
  13. Dillman RO, Davis RB, Green MR, et al. A comparative study of two different doses of cytarabine for acute myeloid leukemia: a phase III trial of Cancer and Leukemia Group B. Blood. 1991;78:2520–2526
  14. Bishop JF, Lowenthal RM, Joshua D, et al. Etoposide in acute nonlymphocytic leukemia. Blood. 1990;75:27–32
  15. Rowe JM, Neuberg D, Friedenberg W, et al. A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood. 2004;103:479–485
  16. Vogler WR, Velez-Garcia E, Weiner RS, et al. A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group study. J Clin Oncol. 1992;10:1103–1111
  17. Wiernik PH, Banks PLC, Case DC, et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood. 1992;79:313–319
  18. Berman E, Heller G, Santorsa J, et al. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood. 1991;77:1666–1674
  19. Arlin Z, Case DC, Moore J, et al. Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia. Lederle Cooperative Group. Leukemia. 1990;4:177–183
  20. Estey EH, Thall PF, Cortes JE, et al. Comparison of idarubicin + ara-c-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts. Blood. 2001;98:3575–3583
  21. Russo D, Malagola M, DeVivo A, et al. Multicenter phase III trial of fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C, and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukemia patients. Br J Haematol. 2005;131:172–179
  22. Van Der Holt B, Sonneveld P, Burnett AK, et al. Daunorubicin and cytarabine compared with daunorubicin, cytarabine and the MDR1 reversal agent PSC-833 in elderly patients with acute myelogenous leukemia. Blood (ASH Annual Meeting Abstracts). 2004;104:Abstract 863
  23. Cripe LD, Li X, Litzow M, Rowe EJM, Luger S, Tallman M. A randomized, placebo controlled, double blind trial of the MDR modulator Zosuquidar, during conventional induction and post-remission therapy for patients >60 years of age with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome: ECOG 3999. Blood (ASH Annual Meeting Abstracts). 2006;108:Abstract 423
  24. Burnett AK, Kell WJ, Milligan AD, et al. The addition of gemtuzumab ozogamicin to induction chemotherapy for AML improves disease free survival without extra toxicity: preliminary analysis of 1115 patients in the MRC AML15 Trial. Blood (ASH Annual Meeting Abstracts). 2006;108:Abstract 13
  25. Stone RM, Mayer RJ. Treatment of the newly diagnosed adult with de novo acute myeloid leukemia. Hematol Oncol Clin North Am. 1993;7:47–64
  26. Champlin R, Gajewski J, Nimer S. Postremission chemotherapy for adults with acute myelogenous leukemia: improvement survival with high-dose cytarabine and daunorubicin consolidation treatment. J Clin Oncol. 1990;8:1199–1206
  27. Cassileth PA, Lynch E, Hines JD, et al. Varying intensity postremission therapy in acute myeloid leukemia. Blood. 1992;79:1924–1930
  28. Schlenk RF, Frohling S, Hartmann F, et al. Intensive consolidation verses oral maintenance therapy in patients 61 years or older with in acute myelogenous leukemia in first remission: results of second randomization of AML HD98-B treatment trial. Leukemia. 2006;20:748–750
  29. Cassileth PA, Harrington DP, Appelbaum FR, et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med. 1998;339:1649
  30. Zittoun RA, Mandelli F, Willemze R, et al. Autologous or allogeneic bone marrow transplantation compared Cawith intensive chemotherapy in acute myelogenous leukemia. N Engl J Med. 1995;332:217
  31. Burnett AK, Goldstone AH, Stevens RMF, et al. Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. Lancet. 1998;351:700
  32. Nathan PC, Sung L, Crump M, Beyene J. Consolidation therapy with autologous bone marrow transplantation in adults with acute myeloid leukemia: a meta-analysis. J Natl Cancer Inst. 2004;96:38
  33. Harousseau J, Cahn J, Pignon B, et al. Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. Blood. 1997;90:2978–2986
  34. Tsimberidou AM, Stavroyianni N, Viniou N, et al. Comparison of allogeneic stem cell transplantation, high-dose cytarabine, and autologous peripheral stem cell transplantation as postremission treatment in patients with de nova acute myelogenous leukemia. Cancer. 2003;97:1721
  35. Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood. 2000;96:4075–4083
  36. Keating S, de Whitte T, Suciu S, et al. The influence of HLA-matched sibling donor availability on treatment outcome for patients with AML: an analysis of the AML 8A study of the EORTC Leukaemia Cooperative Group and GIMEMA. European Organization for Research and Treatment of Cancer. Gruppo Italiano Malattie Ematologiche Maligne dell' Adulto. Br J Haematol. 1998;102:1344–1353
  37. Suciu S, Mandelli F, de Witte , et al. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1):an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial. Blood. 2003;102:1232–1240
  38. Burnett A, Wheatley K, Goldstone A, et al. The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC. AML trial. Br J of Haematol. 2002;118:385–400
  39. Estey EH. Treatment of relapsed and refractory acute myelogenous leukemia. Leukemia. 2000;14:276
  40. Craddock C, Tauro S, Moss P, et al. Biology and management of relapsed acute myeloid leukemia. Br J Haematol. 2005;129:18
  41. Breems DA, Van Putten WL, Huijgens PC, et al. Prognosic index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol. 2005;23:1969
  42. Brown RA, Herzig RH, Wolff SN, et al. High-dose etoposide and cyclophosphamide without bone marrow transplantation for resistant hematologic malignancy. Blood. 1990;76:473–479
  43. Ho AD, Lipp T, Ehninger , et al. Combination of mitoxantrone and etoposide in refractory acute myelogenous leukemia−an active and well-tolerated regimen. J Clin Oncol. 1988;6:213–217
  44. Jackson G, Taylor P, Smith GM, et al. A multicentre, open, noncomparative phase II study of a combination of fludarabine phosphate, cytarabine, and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukaemia and de novo refractory anaemia with excess blasts in transformation. Br J Haematol. 2001;112:127–137
  45. Vignetti M, Orsini E, Petti MC, et al. Probability of long-term disease-free survival for acute myeloid leukemia patients after first relapse: a single-centre experience. Ann Oncol. 1996;7:933–938
  46. Chantry AD, Snowden JA, Craddock C, et al. Long-term outcomes of myeloablation and autologous transplantation of relapsed acute myeloid leukemia in second remission: a British Society of Blood and Marrow Transplantation registry study. Biol Blood Marrow Transplant. 2006;12:1310–1317
  47. Grigg AP, Szer J, Beresford J, et al. Factors affecting the outcome of allogeneic bone marrow transplantation for adult patients with refractory or relapsed acute leukaemia. Br J Haematol. 1999;107:409–418
  48. Boiron JM, Lerner D, Pigneux A, et al. Allogeneic transplantation for patients with advanced acute leukemia: a single center retrospective study of 92 patients. Leuk Lymphoma. 2001;41(3-4):285–296
  49. Mori M, Beatty PG, Graves M, et al. HLA gene and haplotype frequencies in the North American population: the National Marrow Donor Program Donor Registry. Transplantation. 1997;64:1017–1027
  50. Bertz H, Potthoff K, Finke J. Allogeneic stem-cell transplantation from related and unrelated donors in older patients with myeloid leukemia. J Clin Oncol. 2003;21:1480–1484
  51. VanDer Velden VH, te Marvelde JG, Hoogeveen PG, et al. Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. Blood. 2001;97:3197–3204
  52. Tsimberidou AM, Giles FJ, Estey E, et al. The role of gemtuzumab ozogamicin in acute leukaemia therapy. Br J Haematol. 2005;132:398
  53. Tilly H, Castaigne S, Bordessoule D, et al. Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly. J Clin Oncol. 1990;8:272–279
  54. Aul C, Schneider W. The role of low-dose cytosine arabinoside and aggressive chemotherapy in advanced myelodysplastic syndromes. Cancer. 1989;64:1812–1818
  55. Robak T, Szmigielska-Kaplon A, Urbanska-Rys H, et al. Efficacy and toxicity of low-dose melphalan in myelodysplastic syndromes and acute myeloid leukemia with multilineage dysplasia. Neoplasma. 2003;50:172–175
  56. Small D. FLT3 mutations: biology and treatment. Hematology. 2006;178–184
  57. O'Farrell AM, Foran JM, Fiedler W, et al. An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin Cancer Res. 2003;15:5465–5476
  58. Fiedler W, Serve H, Dohner H, et al. A phase I study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for disease. Blood. 2005;105:986–993
  59. O'Farrell AM, Yuen HA, Smolich B, et al. Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia. Leuk Res. 2004;28:679–689
  60. Fiedler W, Mester R, Tinnefeld H, et al. A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia. Blood. 2003;102:2763–2767
  61. Giles FJ, Stopeck AT, Silverman LR, et al. SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients refractory acute myeloid leukemia or myelodysplastic syndromes. Blood. 2003;102:795–801
  62. Smith BD, Levis M, Beran M, et al. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood. 2004;103:3669–3676
  63. Knapper S, Burnett AK, Littlewood T, et al. A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. Blood. 2006;108:3262–3270
  64. Stone RM, DeAngelo DJ, Klimek V, et al. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood. 2005;105:54–60
  65. Stone RM, Klimek V, DeAngelo DJ, et al. Oral PKC412 has activity in patients with mutant FLT3 acute myeloid leukemia: a phase II trial. Proc Am Soc Clin Oncol. 2003;22;Abstract. 2265
  66. DeAngelo DJ, Stone RM, Heaney ML, et al. Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myeloid leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics. Blood. 2006;108:3674–3681
  67. Levis M, Pham R, Smith BD, et al. In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic toxic effects. Blood. 2004;104:1145–1150
  68. Levis M, Smith BD, Beran M, et al. A randomized, open-label study of Lestaurtinib (CEP-701), an oral FLT3 inhibitor, administered in sequence with chemotherapy in patients with relapsed AML harboring FLT3 activating mutations: clinical response correlates with successful FLT3 inhibition. Blood (ASH Annual Meeting Abstracts). 2005;106:Abstract 403
  69. Stone RM, Fischer T, Paquette R, et al. Phase IB study of PKC-412, an oral FLT3 kinase inhibitor, in sequential and simultaneous combinations with daunorubicin and cytarabine induction and high-dose cytarabine consolidation in newly diagnosed adult patients with acute myeloid leukemia under age 61. Blood (ASH Annual Meeting Abstracts). 2006;108:Abstract 157
  70. DeAngelo DJ, Amrein PC, Kovacsovics TJ, et al. Phase 1/2 study of Tandutinib (MLN518) plus standard induction chemotherapy in newly diagnosed acute myelogenous leukemia. Blood (ASH Annual Meeting Abstracts). 2006;108:Abstract 158
  71. Le DT, Shannon KM. Ras processing as a therapeutic target in hematologic malignancies. Curr Opin Hematol. 2002;9:308–315
  72. Korycka A, Smolewski P, Robak T. The influence of farnesyl protein transferase inhibitor R115777 (Zarnestra) alone and in combination with purine nucleoside analogs on acute myeloid leukemia progenitors in vitro. Eur J Haematol. 2004;73:418–426
  73. Liesveld JL, Lancet JE, Rosell KE, et al. Effects of farnesyl transferase inhibitor R115777 on normal and leukemic hematopoiesis. Leukemia. 2003;17:1806–1812
  74. Lancet JE, Gojo I, Gotlib J, et al. A phase 2 study of the farnesyl transferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia. Blood. 2007;109:1387–1394
  75. Alvarez RH, Kantarjian H, Garcia-Manero G, et al. Farnesyl transferase inhibitor (Tipifarnib, Zarnestra) in combination with standard chemotherapy with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia or high risk myelodysplastic syndrome. Blood (ASH Annual Meeting Abstracts). 2006;108:Abstract 1999
  76. Fandy TE, Carraway H, Gore S. DNA demethylating agents and histone deacetylase inhibitors in hematologic malignancies. Cancer J. 2007;13:40–48
  77. Issa JP, Garcia-Manero G, Giles FJ, et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies. Blood. 2004;103:1635–1640
  78. Al-Ali HK, Schwind S, Becker C, Mueller C, Niederwieser D. 5-Azacytidine induces hematologic responses in a high proportion of patients with acute myeloid leukemia refractory to or not eligible for intensive chemotherapy. Blood (ASH Annual Meeting Abstracts). 2006;108:Abstract 1953
  79. Garcia-Manero G, Yang H, Sanchez-Gonzalez B, et al. Final results of a phase 1 study of the histone deacetylase inhibitor Vorinostat (suberoyanilide hydroxamic acid SAHA), in patients with leukemia and myelodysplastic syndrome. Blood (ASH Annual Meeting Abstracts). 2005;106:Abstract 2801
  80. Kuendgen A, Schmid M, Schlenk R, et al. The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia. Cancer. 2006;106:112–119
  81. Kuendgen A, Knipp S, Fox F, et al. Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia. Ann Hematol. 2005;84(Suppl 13):61–66
  82. Byrd JC, Marcucci G, Parthun MR, et al. A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood. 2005;105:959–967
  83. Maslak P, Chanel S, Camacho LH, et al. Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome. Leukemia. 2006;20:212–217
  84. Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, et al. Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. Blood. 2006;108:3271–3279
  85. Garcia-Manero G, Yang AS, Giles F, et al. Phase 1/2 study of the oral isotype selective histone deacetylase (HDAC) inhibitor MGCD0103 in combination with azacitidine in patients with high-risk myelodysplastic syndrome or acute myelogenous leukemia. Blood (ASH Annual Meeting Abstracts). 2006;108:Abstract 1954
  86. Mahadevan D, List AF. Targeting the multidrug resistance-1 transporter in AML: molecular regulation and therapeutic strategies. Blood. 2004;104:1940–1951
  87. List AF, Kopecky KJ, William CL, et al. Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. Blood. 2001;98:3212–3220
  88. Greenberg PL, Lee SJ, Advani R, et al. Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). J Clin Oncol. 2004;22:1078–1086
  89. Cripe L, Tallman M, Karanes C. A phase II trial of zosuquidar (LY335979), a modulator of P-glycoprotein (P-gp) activity, plus daunorubicin and high-dose cytarabine in patients with newly diagnosed secondary acute leukemia (AML), refractory anemia with excess blasts in transformation (RAEB-t) or relapsed/refractory AML [abstract]. Blood. 2001;98:595
  90. Chanan-Khan A. Bcl-2 antisense therapy in hematologic malignancies. Curr Opin Oncol. 2004;16:581–585
  91. Tallman MS. New strategies for the treatment of acute myeloid leukemia including antibodies and other novel agents. Hematology Am Soc Hematol Educ Program. 2005;143–150
  92. Marcucci G, Byrd JC, Dai G, et al. Phase 1 and pharmacodynamic studies of G3139, a bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia. Blood. 2003;101:425–432
  93. Marcucci G, Stock W, Dai G, et al. Phase 1 study of oblimersen sodium, an antisense to bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity. J Clin Oncol. 2005;23:3404–3411
  94. Tallman MS, Gilliland DG, Rowe JM. Drug therapy for acute myeloid leukemia. Blood. 2005;106:1154–1163
  95. Roboz GJ, Giles FJ, List AF, et al. Phase 1 study of PTK787/ZK222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome. Leukemia. 2006;20:952–957
  96. Giles FJ, Bellamy WT, Estrov Z, et al. The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia or myelodysplastic syndrome. Leuk Res. 2006;30:801–811
  97. Fiedler W, Serve H, Dohner H, et al. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia or not amenable to conventional therapy for the disease. Blood. 2005;105:986–993
  98. Fiedler W, Mesters R, Tinnefeld H, et al. A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia. Blood. 2003;102:2763–2767
  99. Karp JE, Gojo I, Pili R, et al. Targeting vascular endothelial growth factor for relapsed and refractory adult acute myeloid leukemias: therapy with sequential 1 beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab. Clin Cancer Res. 2004;10:3577–3585
  100. Zahiragic L, Schliemann C, Bieker R, Berdel WE, Mesters RM. Bevacizumab reduces VEGF expression in patients with relapsed and/or refractory acute myeloid leukemia without clinical antileukemic activity. Blood (ASH Annual Meeting Abstracts). 2006;108:Abstract 4543
  101. Thomas DA, Estey E, Giles FJ, et al. Single agent thalidomide in patients with relapsed or refractory acute myeloid leukemia. Br J Haematol. 2003;123:436–441
  102. Cortes J, Kantarjian H, Albitar M, et al. A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome. Cancer. 2003;97:1234–1241
  103. Faderl S, Gandhi V, O'Brien S, et al. Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-c) in relapsed and refractory acute leukemias. Blood. 2005;105:940–947
  104. Kantarjian H, Gandhi V, Cortes J, et al. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood. 2003;102:2379–2386
  105. Faderl S, Verstovsek S, Cortes J, et al. Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia in patients 50 years of age or older. Blood. 2006;108:45–51

PII: S0301-472X(09)00130-1

doi: 10.1016/j.exphem.2009.04.002

Experimental Hematology
Volume 37, Issue 6 , Pages 649-658 , June 2009

Article Tools